> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Discuss GSK NDA for OTC Nicotine Spray
- URL: https://www.fdaweb.com/panel-to-discuss-gsk-nda-for-otc-nicotine-spray/
- Published: 2019-08-16T12:00:00.000Z
- Updated: 2026-09-15T01:44:17.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5144786

*Federal Register* notice: FDA has announced a 9/18 Nonprescription Drugs Advisory Committee meeting on a GlaxoSmithKline Consumer Healthcare NDA for the over-the-counter marketing of nicotine oral spray (1 mg). The proposed OTC use is to reduce withdrawal symptoms, including nicotine craving, associated with quitting smoking in adults aged 18 years and older. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-17724.pdf?ref=fdaweb.com).